BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Unsustainable U.S. Electrophysiology Segment Growth Rate: Levi & Korsinsky

Time-Sensitive: Allegations Focus on Concealed Unsustainability of U.S. EP Segment Growth Rate

BSX INVESTOR ALERT

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Boston Scientific Corporation (NYSE: BSX) of a pending securities class action. Class Period: July 23, 2025 through February 3, 2026. Check if you can recover your investment losses or contact Joseph E. Levi, Esq. at [e-mail] | [phone].

Boston Scientific shares fell $16.12 per share on February 4, 2026, a decline of approximately 17.6%, after the Company disclosed disappointing U.S. EP sales and issued fiscal 2026 guidance well below expectations. The Court has set May 4, 2026 as the deadline to apply for lead plaintiff appointment.

What the Company Allegedly Knew About Approaching a Tipping Point

The lawsuit asserts that management was aware the U.S. EP segment's rapid growth rate was unsustainable and was approaching a tipping point earlier than the market anticipated. Despite this alleged knowledge, the Company repeatedly elevated full-year guidance and issued overwhelmingly positive statements about the EP division's trajectory throughout the second half of 2025.

The action claims management touted "continued market growth," projected PFA penetration expanding from 50% to 80% by 2028, and described the EP market as "the largest, fastest-growing market in med tech" without adequately disclosing headwinds that were already materializing.

Medtech Growth Sustainability and the EP Segment

The securities action raises important questions about growth sustainability disclosure obligations in the medical device sector:

- Management allegedly knew procedure volume growth was slowing in the U.S. EP market but continued to project accelerating adoption

- Competitive pressures from established rivals were allegedly intensifying even as the Company claimed it could "insulate" its position through ecosystem advantages

- Reimbursement and regulatory headwinds affecting procedure volumes were allegedly known but not disclosed to investors

- The Company raised full-year guidance on multiple occasions during the Class Period, as alleged, despite awareness of these adverse trends

- The gap between management's public optimism and the EP segment's actual trajectory allegedly widened throughout the Class Period

Why Alleged Growth Sustainability Disclosures Matter to Investors

When a company's dominant growth segment faces decelerating momentum, timely and transparent disclosure allows investors to make informed decisions. As pleaded, Boston Scientific's management instead painted a picture of durable, differentiated growth while the underlying dynamics were shifting.

The complaint contends that by the time the Company acknowledged "slower than expected market growth alongside increased competition" on February 4, 2026, shareholders had been purchasing stock at artificially inflated prices for months.

"Investors deserve transparency about material risks that could affect their investments. When a company's fastest-growing segment faces significant headwinds, shareholders are entitled to know before the market corrects." -- Joseph E. Levi, Esq.

Speak with an attorney about recovering damages or call Joseph E. Levi, Esq. at [phone].

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.